8 completed, 6 not yet recruiting, 3 recruiting, 3 unknown. 9 Not applicable, 5 Phase 2, 3 Phase 4, 2 Phase 3, 1 Phase 1.
Follow HEPATITIS C (HCV): new trials by email Literature Review of HEPATITIS C (HCV) trials Research Report on HEPATITIS C (HCV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine Standard of Care (Patient Navigation to Off-Site Clinic), Status-Neutral Telehealth Concierge (SN-THR) - HIV, Substance Use Disorder (SUD) | Not applicable | Not yet recruiting | University of Miami | 200 | 2027-05-01 | 2026-11-12 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-11-18 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs Partner navigation intervention booster session - HEPATITIS C (HCV), Opioid Use Disorder | Not applicable | Not yet recruiting | University of California, San Francisco | 50 | 2026-09-01 | 2026-06-08 |
| Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3) Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID) - HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV) | Not applicable | Not yet recruiting | University of Georgia | 50 | 2026-08-01 | 2025-12-18 |
| Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing PPP-CCM - HEPATITIS C (HCV) | Not applicable | Recruiting | University of Washington | 444 | 2026-06-01 | 2026-11-12 |
| Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic Rapid Fingerstick Test, Blood Draw for lab test - HIV Testing, HEPATITIS C (HCV) | Recruiting | West Virginia University | 200 | 2026-01-21 | 2026-08-13 | |
| Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France Community screening for hepatitis B, C and delta in the Mongolian population living in France - HEPATITIS C (HCV), Hepatitis B Virus (HBV) | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 2000 | 2025-09-01 | 2025-06-26 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health HEPATITIS C (HCV) | Enrolling by invitation | Corey DeStefano | 60 | 2025-03-15 | 2026-08-05 | |
| Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384 HEPATITIS C (HCV) | Unknown | CerbaXpert | 45 | 2024-10-01 | 2024-10-03 | |
| Lay User Evaluation of the Panbio™ HCV Self-Test Panbio™ HCV Self Test - HEPATITIS C (HCV) | Not applicable | Unknown | Abbott Rapid Dx | 1185 | 2024-10-01 | 2024-09-20 |
| Persuasive Health Communication Intervention for HIV/HCV Video Format with Captions, Video Format without Captions, Health Educator - Human Immunodeficiency Virus (HIV), Hepatitis C (HCV) | Not applicable | Completed | University of South Florida | 2000 | 2023-12-04 | 2026-10-13 |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk Health kiosk - Opioid-Related Disorders, Hepatitis C (HCV) | Not applicable | Active not recruiting | April M Young | 752 | 2023-03-06 | 2026-08-18 |
| A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection Faldaprevir, TD-6450, Ribavirin - Hepatitis C Viral Infection, Chronic Hepatitis C | Phase 2 | Completed | Trek Therapeutics, PBC | 25 | 2016-05-01 | 2017-10-17 |
| A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection Faldaprevir, TD-6450, Ribavirin - Hepatitis C Viral Infection, Chronic Hepatitis C | Phase 2 | Completed | Trek Therapeutics, PBC | 16 | 2015-10-01 | 2017-01-30 |
| Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin - Chronic Hepatitis C, Hepatitis C (HCV) | Phase 3 | Completed | AbbVie | 25 | 2015-06-01 | 2017-10-03 |
| Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults Ombitasvir/ABT-450/Ritonavir, Dasabuvir, Ribavirin (RBV) - Chronic Hepatitis C, Hepatitis C (HCV) | Phase 2 | Completed | AbbVie | 46 | 2015-06-01 | 2017-10-31 |
| Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases Naderin, Standard Therapy - Malignant Neoplasms, Tuberculosis (TB) | Phase 2 / Phase 3 | Completed | MIPO Clinic | 75 | 2013-05-15 | 2026-06-30 |
| Acupuncture as an Adjunctive Treatment for Hepatitis C Patients Acupuncture - Hepatitis C (HCV), Acupuncture | Not applicable | Unknown | Assy Nimer | 2013-01-01 | 2012-12-17 |
Showing 20 of 22. Sign in to see all of them.
Hepatitis C (22) · Hepatitis C, Chronic (5) · Acquired Immunodeficiency Syndrome (3) · Hepatitis B (3) · Opioid-Related Disorders (3) · Substance-Related Disorders (3) · Carcinoma, Hepatocellular (1) · Drug Overdose (1) · Harm Reduction (1) · Hepatitis D (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Neoplasms (1) · Neutropenia (1) · Sexually Transmitted Diseases (1)
Blood-Borne Infections (22) · Communicable Diseases (22) · Digestive System Diseases (22) · Flaviviridae Infections (22) · Hepatitis (22) · Hepatitis, Viral, Human (22) · Infections (22) · RNA Virus Infections (22) · Virus Diseases (22) · Liver Diseases (21) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Disease Attributes (6) · Chronic Disease (5) · Hepatitis, Chronic (5)
Ribavirin (5) · Sofosbuvir (3) · dasabuvir (3) · sofosbuvir-velpatasvir drug combination (3) · velpatasvir (3) · Standard of Care (2) · faldaprevir (2) · ombitasvir (2) · Acupuncture Therapy (1) · Blood Specimen Collection (1) · Community Health Workers (1) · Ritonavir (1) · filibuvir (1) · paritaprevir (1) · sodium nucleinate (1)
AbbVie (2) · Trek Therapeutics, PBC (2) · AbbVie (prior sponsor, Abbott) (1) · Abbott Rapid Dx (1) · April M Young (1) · Assy Nimer (1) · CerbaXpert (1) · Corey DeStefano (1) · Duke University (1) · Hospices Civils de Lyon (1) · Lifespan (1) · MIPO Clinic (1) · Patrick Grace (1) · Pfizer (1) · University of California, San Francisco (1)
United States (13) · France (3) · New Zealand (2) · Australia (1) · Canada (1) · Germany (1) · Israel (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Emily Dumas, PhD (2) · Tarek Hassanein, MD (2) · April M Young, PhD (1) · Armen Henderson, MD (1) · Dana Bechtold, DO (1) · Daniel Cohen, MD (1) · Diana Finkel, DO (1) · Ed Gane, MD (1) · Hansel E Tookes, MD, MPH (1) · Huma Qureshi, MD (1) · Judith Tsui, MD, MPH (1) · Meghan Morris, PhD, MPH (1) · Mohammed Majam, BSc, MBA (1) · Roland C Merchant, MD (1)
PMID 24428468, PMID 26100711, PMID 34312544, PMID 36972796, PMID 38431295, PMID 39134444, PMID 41027703, PMID 41322680
2014 (1), K01DA059329 (1), K24DA061103 (1), R01DA055533 (1), R01DA055872 (1), R01DA062638 (1), R01DA065187 (1), R34DA061732 (1), U01AI195193 (1)